Myriad Genetics Inc. History - Founding, Milestones & Growth Journey

History

Year	Detail
1991	Myriad Genetics was founded.
1996	Developed the first genetic test to assess the risk of hereditary breast and ovarian cancer.
2010	The launch of Prolaris.
2012	Myriad expanded internationally with the opening of a laboratory in Munich, Germany.
2013	Myriad launched MyRisk Hereditary Cancer.
2022	Myriad Genetics partnered with Intermountain Precision Genomics.
2023	Myriad Genetics collaborated with the Leading Cancer Center.
2024	Myriad Genetics acquired Precise Tumor.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.